English 
Español de México 
Tiếng Việt 
简体中文 
Let's Bump Up the Boosters!
Did you know that even if you’ve been fully vaccinated against COVID-19 (two doses), your protection against the virus may decrease over time? That’s why doctors and the CDC are recommending everyone ages 6 months and over receive the Omicron Bivalent booster shot, about two months after their initial series of vaccinations or after a previous booster shot.
More Information About Boosters
- Why Boost? COVID-19 vaccine boosters can further enhance or restore protection that might have decreased over time after your primary vaccination series. People are protected best from severe COVID-19 illness when they stay up to date with their COVID-19 vaccines, which includes getting all recommended boosters when eligible.
- When to Boost? COVID-19 vaccine boosters can further enhance or restore protection that might have decreased over time after your primary vaccination series. People are protected best from severe COVID-19 illness when they stay up to date with their COVID-19 vaccines, which includes getting all recommended boosters when eligible.
- Who Can Get A Booster: As of December 14, 2022, in addition to all adults, children ages 6 months and up are recommended to get an Omicron Bivalent Booster at least 2 months after 2nd primary series dose. Find out more information. The FDA has authorized the updated (bivalent) Moderna and Pfizer-BioNTech COVID-19 vaccines to include use for children 6 months of age and up
- Authorized Use: Emergency uses of the vaccines have been approved or licensed by the FDA under the Emergency Use Authorization (EUA) to prevent Coronavirus Disease 2019 (COVID-19). The Moderna COVID-19 Vaccine is authorized in individuals 6 months of age and older as a primary series. The Moderna COVID-19 Vaccine, Bivalent is authorized as a booster dose in individuals 6 years of age and older. The FDA decision is based on the totality of the scientific evidence available showing that the product may be effective to prevent COVID-19 during the COVID-19 pandemic and that the known and potential benefits of the product outweigh the known and potential risks of the product.
